Absci to Join June 15 Panel on AI Drug Discovery Shift
ABSI•Absci will join a June 15 virtual investor panel titled “Partnering to Power the New Era of Drug Discovery” alongside MindWalk Holdings and a leading AI compute provider. The panel will examine the shift toward curated biological context layers to prevent AI hallucinations and strengthen drug target discovery workflows.
1. Absci Joins Virtual Investor Panel
On June 15, Absci will participate in a virtual investor panel titled “Partnering to Power the New Era of Drug Discovery” alongside MindWalk Holdings and a leading AI compute provider. The event, though small, positions Absci within a key industry discussion on optimizing AI-driven research workflows.
2. Industry Debate Focuses on Biological Context Layers
The panel will explore why durable advantages in AI drug discovery lie in high-quality, curated biological knowledge rather than ever-larger models. This discussion underscores the emerging consensus that integrated biological context layers are essential to prevent expensive AI errors and enhance target discovery reliability.
